Erasca (ERAS)
NASDAQ:ERAS
Want to see ERAS full AI Analyst Report?
Top Page
Erasca
(NASDAQ:ERAS)
Select Model
Select Model
Rating:45Neutral
Price Target:
$9.00
▼(-52.66% Downside)
Action:ReiteratedDate:04/30/26
The score is primarily held down by weak financial performance (no revenue, sizable losses, and ongoing cash burn) and a bearish technical setup (trading well below major moving averages). Corporate events provide some offset due to encouraging early Phase 1 signals, but legal and safety risks limit the uplift, while valuation support is limited given a negative P/E and no dividend.
Positive Factors
Clinical Efficacy
Robust early monotherapy signals across multiple RAS-mutant tumor types (high unconfirmed ORRs and substantial ctDNA declines) suggest the asset can meaningfully impact hard-to-treat populations. Durable activity in heavily pretreated patients supports long-term clinical value and partner interest.
Negative Factors
Cash Burn & No Revenue
Persistent large losses and negative operating/free cash flow mean the company remains dependent on external financing to sustain R&D. Continued burn without commercial revenue increases dilution risk, may force financing-driven program pacing changes, and constrains long‑term financial flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical Efficacy
Robust early monotherapy signals across multiple RAS-mutant tumor types (high unconfirmed ORRs and substantial ctDNA declines) suggest the asset can meaningfully impact hard-to-treat populations. Durable activity in heavily pretreated patients supports long-term clinical value and partner interest.
Read all positive factors
Erasca (ERAS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.39B
Dividend YieldN/A
Average Volume (3M)6.76M
Price to Earnings (P/E)―
Beta (1Y)1.76
Revenue GrowthN/A
EPS Growth41.14%
CountryUS
Employees103
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.44
Shares Outstanding310,799,560
10 Day Avg. Volume8,687,046
30 Day Avg. Volume6,757,213
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)3.24
Price to Sales (P/S)0.00
P/FCF Ratio-11.03
Enterprise Value/Market Cap0.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.52K
Enterprise Value/Ebitda-26.60
Forecast
1Y Price Target
$20.20Price Target Upside6.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)-0.43
Revenue Forecast (FY)N/A
Erasca Business Overview & Revenue Model
Company Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK...
How the Company Makes Money
Erasca is a clinical-stage biotechnology company and, as such, it does not primarily generate recurring revenue from commercial product sales because it does not have any approved products for sale. Its reported revenue, when present, is typically...
Erasca Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
55
Neutral
Cash Flow
34
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -3.11M | 0.00 | -3.73M | -2.64M | -829.00K |
| EBITDA | -128.30M | -153.28M | -121.31M | -240.16M | -121.94M |
| Net Income | -124.55M | -161.65M | -125.04M | -242.81M | -122.76M |
Balance Sheet | |||||
| Total Assets | 396.15M | 502.53M | 395.30M | 514.91M | 501.42M |
| Cash, Cash Equivalents and Short-Term Investments | 276.07M | 298.31M | 312.35M | 435.62M | 414.48M |
| Total Debt | 47.14M | 51.89M | 55.86M | 55.10M | 18.79M |
| Total Liabilities | 70.98M | 79.03M | 78.61M | 103.06M | 44.89M |
| Stockholders Equity | 325.17M | 423.50M | 316.69M | 411.85M | 456.53M |
Cash Flow | |||||
| Free Cash Flow | -95.58M | -131.98M | -102.99M | -119.81M | -98.48M |
| Operating Cash Flow | -95.45M | -109.42M | -101.22M | -103.26M | -79.60M |
| Investing Cash Flow | 100.42M | -156.62M | -91.22M | -71.08M | -64.59M |
| Financing Cash Flow | 1.10M | 240.70M | 1.29M | 98.08M | 439.40M |
Erasca Technical Analysis
Positive
19.01
Price Trends
14.74
Positive
10.20
Positive
6.05
Positive
Market Momentum
1.12
Negative
69.64
Neutral
80.55
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ERAS, the sentiment is Positive. The current price of 19.01 is above the 20-day moving average (MA) of 16.52, above the 50-day MA of 14.74, and above the 200-day MA of 6.05, indicating a bullish trend. The MACD of 1.12 indicates Negative momentum. The RSI at 69.64 is Neutral, neither overbought nor oversold. The STOCH value of 80.55 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ERAS.
Erasca Risk Analysis
Erasca disclosed 85 risk factors in its most recent earnings report. Erasca reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Erasca Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $1.56B | -6.21 | -32.49% | ― | ― | -101.89% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $259.50M | -1.44 | -29.13% | ― | -51.43% | 20.51% | |
49 Neutral | $656.24M | -2.86 | -14.25% | ― | -0.30% | 56.14% | |
47 Neutral | $1.32B | -12.39 | -42.90% | ― | ― | 13.36% | |
45 Neutral | $3.39B | -9.06 | -34.48% | ― | ― | 41.14% |
* Healthcare Sector Average
ERAS
Erasca
10.90
9.51
684.17%
ARCT
Arcturus Therapeutics
9.13
-2.25
-19.77%
ARVN
Arvinas Holding Company
10.26
3.45
50.66%
OLMA
Olema Pharmaceuticals
15.19
10.52
225.27%
BCAX
Bicara Therapeutics Inc.
23.78
10.65
81.11%
Erasca Corporate Events
Business Operations and StrategyProduct-Related Announcements
Erasca Reports Encouraging Phase 1 Data for ERAS-0015
Positive
Apr 27, 2026
On April 27, 2026, Erasca reported positive preliminary Phase 1 dose escalation results for its pan-RAS molecular glue ERAS-0015 in RAS-mutant solid tumors, drawing on data from the AURORAS-1 trial in the U.S. and JYP0015M101 in China. The drug sh...
Business Operations and StrategyLegal ProceedingsProduct-Related Announcements
Erasca Highlights ERAS-0015 Phase 1 Data Update
Negative
Apr 27, 2026
On April 27, 2026, Erasca said it would host a conference call and webcast that day to discuss preliminary Phase 1 dose‑escalation data for its pan‑RAS molecular glue candidate ERAS‑0015 in patients with RAS‑mutant solid tu...
Business Operations and StrategyProduct-Related Announcements
Erasca Tightens Timeline for ERAS-0015 Phase 1 Data
Positive
Apr 21, 2026
On April 21, 2026, Erasca, Inc. announced it had tightened the expected timing for a Phase 1 monotherapy data readout for its pan-RAS molecular glue candidate ERAS-0015 to no later than mid-May 2026, from a prior target of the first half of 2026. ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.